- 51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile1
- Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases
- Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases
Holzkirchen, September 14, 2017 – Sandoz, a Novartis …